Health
FDA warns GLP-1 weight loss medications can cause rare blindness-causing eye condition.
FDA reviewed 126 trials and found 15 probable NAION cases, with rates higher among users than controls.
OriginalSourceThe IndependentUnited KingdomLeanCenter-leftCredibilityPublished15:22 UTCRatings: AllSides, MBFCSourceThe IndependentUnited KingdomLeanCenter-leftCredibilityPublished15:22 UTCRatings: AllSides, MBFC
“FDA adds rare blindness warning to popular GLP-1 drugs”
FDA adds rare blindness warning to popular GLP-1 drugs
Key points
- FDA announced a new warning label for GLP-1 drugs including Ozempic, Wegovy, Zepbound, and Mounjaro.
- The warning concerns non-arteritic anterior ischemic optic neuropathy, a rare cause of vision loss.
- An FDA review followed a 2024 paper linking the condition to semaglutide use.
- Analysis of over 125 trials showed about 6 in 100,000 patients affected for at least a year.
- The rate is higher than the under 4 per 100,000 in placebo groups, per FDA data.
Other reports
- SourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS NewsSourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS News
“FDA warns of rare vision-loss side effect from GLP-1 drugs”
- SourceMintIndiaOwner: HT MediaLeanCenterCredibilityRatings: AllSides, MBFCRead at MintSourceMintIndiaOwner: HT MediaLeanCenterCredibilityRatings: AllSides, MBFCRead at Mint
- SourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars TechnicaSourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars Technica
“GLP-1 drugs may increase risk of vision loss from rare condition, FDA warns”
- SourceThe NationalUnited Arab EmiratesLeanUnratedCredibilityUnratedRead at The NationalSourceThe NationalUnited Arab EmiratesLeanUnratedCredibilityUnratedRead at The National
“FDA orders new warning on GLP-1 drugs over potential risk of blindness”
- SourceGlobal NewsCanadaOwner: Global Television NetworkLeanUnratedCredibilityUnratedRead at Global NewsSourceGlobal NewsCanadaOwner: Global Television NetworkLeanUnratedCredibilityUnratedRead at Global News
- SourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBCSourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBC
“Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness”
- SourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The GuardianSourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Guardian
“FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications”
- SourceBusinessLineIndiaLeanUnratedCredibilityUnratedRead at BusinessLineSourceBusinessLineIndiaLeanUnratedCredibilityUnratedRead at BusinessLine
“FDA flags possible risk of rare eye condition with GLP-1 drugs, orders new safety warning”
How it got here
The Independent publishes the article.
concise.news reads it.
Grouped with 8 other reports as story 8.
The Brief ranks it 8th.
8 8 FDA warns GLP-1 weight loss medications can cause rare blindness-causing eye condition.
FDA reviewed 126 trials and found 15 probable NAION cases, with rates higher among users than controls.